Boomfish Wealth Group LLC Sells 1,151 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Boomfish Wealth Group LLC lowered its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 20.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,383 shares of the pharmaceutical company’s stock after selling 1,151 shares during the period. Boomfish Wealth Group LLC’s holdings in Vertex Pharmaceuticals were worth $2,291,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Community Financial Services Group LLC acquired a new stake in shares of Vertex Pharmaceuticals during the second quarter worth $26,000. Meeder Asset Management Inc. bought a new position in shares of Vertex Pharmaceuticals during the second quarter worth approximately $26,000. Elevation Wealth Partners LLC raised its position in Vertex Pharmaceuticals by 103.7% during the second quarter. Elevation Wealth Partners LLC now owns 55 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 28 shares in the last quarter. Pingora Partners LLC bought a new position in shares of Vertex Pharmaceuticals in the 2nd quarter valued at $32,000. Finally, City Holding Co. grew its position in shares of Vertex Pharmaceuticals by 128.1% in the 2nd quarter. City Holding Co. now owns 73 shares of the pharmaceutical company’s stock valued at $36,000 after buying an additional 41 shares during the last quarter. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Down 2.1%

Shares of NASDAQ VRTX opened at $523.93 on Friday. The company has a market cap of $132.97 billion, a PE ratio of 30.50, a PEG ratio of 2.57 and a beta of 0.28. Vertex Pharmaceuticals Incorporated has a 52-week low of $403.16 and a 52-week high of $560.25. The firm’s 50-day moving average price is $523.52 and its 200-day moving average price is $483.25.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, August 3rd. The pharmaceutical company reported $4.73 earnings per share for the quarter, missing analysts’ consensus estimates of $4.74 by ($0.01). The firm had revenue of $3.33 billion during the quarter, compared to the consensus estimate of $3.23 billion. Vertex Pharmaceuticals had a net margin of 35.00% and a return on equity of 23.09%. The firm’s revenue was up 12.5% compared to the same quarter last year. During the same period in the prior year, the company posted $4.52 EPS. As a group, equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 16.74 EPS for the current fiscal year.

Analyst Ratings Changes

VRTX has been the topic of a number of analyst reports. Wall Street Zen raised shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, October 17th. Leerink Partners started coverage on shares of Vertex Pharmaceuticals in a research note on Monday, September 21st. They issued an “outperform” rating and a $594.00 target price for the company. Barclays increased their price objective on Vertex Pharmaceuticals from $615.00 to $617.00 and gave the stock an “overweight” rating in a report on Wednesday, August 5th. Rothschild & Co Redburn boosted their price target on shares of Vertex Pharmaceuticals from $570.00 to $580.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Finally, JPMorgan Chase & Co. reaffirmed an “overweight” rating and issued a $560.00 price target (up from $515.00) on shares of Vertex Pharmaceuticals in a report on Friday, September 11th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $579.81.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.